XML 44 R31.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue- Gilead Science Inc (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 14, 2022
Jun. 30, 2024
Oct. 31, 2022
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Collaboration And Other Agreements [Line Items]                
Revenues       $ 110,708 $ 10,397 $ 130,609 $ 48,029  
Deferred revenue, current       23,308   23,308   $ 21,651
Deferred revenue, net of current portion       55,503   55,503   59,243
Gilead | 2022 Gilead Collaboration And License Agreement                
Collaboration And Other Agreements [Line Items]                
Non-refundable upfront payment     $ 60,000          
Revenues       400 400 900 1,000  
Deferred revenue       57,400   57,400   58,300
Deferred revenue, current       1,900   1,900   2,200
Deferred revenue, net of current portion       55,500   55,500   56,100
Potential target nomination, option fees and milestone payments $ 1,700,000              
Gilead | Gilead First Research Program                
Collaboration And Other Agreements [Line Items]                
Revenues   $ 3,300   400 100 2,400 100  
Deferred revenue       16,400   16,400   14,900
Deferred revenue, current       $ 16,400   $ 16,400   11,800
Deferred revenue, net of current portion               $ 3,100
Revenue, remaining performance obligation, amount         15,700   15,700  
Potential option fees         $ 10,000   $ 10,000